Agoracom: Small Cap Investment - Resverlogix Corp. - Victoza joins Jardiance as effective for reducing MACE in diabetics

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Victoza joins Jardiance as effective for reducing MACE in diabetics

posted on Mar 04, 2016 04:30PM

Remember the Eli Lilly SGLT2 inhibitor Jardiance(empagliflozin) EMPA-REG OUTCOME trial results that were revealed last year that showed reduced MACE in high cardiovascular risk diabetics? Today, it was announced that Novo Nordisk's GLP-1 receptor agonist Victoza (liraglutide) was also effective in reducing MACE in high cardiovascular risk diabetics. Here's a FiercePharma article on this story. Full results won't be revealed until this summer's American Diabetes Association meeting, so we don't know the absolute or relative risk reductions, or which components of the MACE were reduced.

What does this mean for RVX-208? Not much really. However, if like Jardiance the effect on MACE elicited by Victoza is only modest, this will indirectly put RVX-208 into the spotlight.

Speaking of indirect spotlight.....keep in mind that Merck's CETP inhibitor anacetrapib REVEAL trial is still ongoing with topline sometime around Q1 2017. This is the last CETP inhibitor Phase 3 trial standing. Depending on the results of this trial, the spotlight may shine differently on RVX-208 as well.